Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause

Mackay Memorial Hospital

Status: Not yet enrolling

Conditions: Platelet-rich Plasma; Vaginal Atrophy; Estrogen Replacement Therapy; Menopause

Treatments: Drug: Vaginal estrogen supplement; Procedure: Platelet-rich plasma injection

Study type: Observational

Funder types: Other

Identifiers

NCT05483634

19MMHIS340e

Details and patient eligibility

About

The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia.

The treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.

Enrollment: 40 estimated patients

Sex: Female

Ages: 45 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with menopause
• Patients with symptoms of genitourinary syndrome of menopause

Exclusion criteria

• Genitourinary bleeding or infection without definitive diagnosis
• Coagulopathy
• Allergy to medication or therapy related with the treatment
• Chronic disease that might influence outcome
• Using medication that might influence outcome in 30 days
• Using hormone or steroid within 8 weeks

Trial design

40 participants in 1 patient group

Genital urinary symptoms of menopause

Description:

Menopause for one year, or age above 45 with symptoms of GSM

Treatment:

Procedure: Platelet-rich plasma injection

Drug: Vaginal estrogen supplement